Discriminant analysis of 18F-fluorothymidine kinetic parameters to predict survival in patients with recurrent high-grade glioma

Clinical Cancer Research

Volumn 17, Issue 20, 2011, Pages 6553-6562

  Wardak, Mirwais ^a   Schiepers, Christiaan ^a   Dahlbom, Magnus ^a   Cloughesy, Timothy ^a   Chen, Wei ^a   Satyamurthy, Nagichettiar ^a   Czernin, Johannes ^a   Phelps, Michael E ^a   Huang, Sung Cheng ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3' FLUOROTHYMIDINE F 18; BEVACIZUMAB; IRINOTECAN; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; 3' FLUOROTHYMIDINE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DIAGNOSTIC AGENT; DRUG DERIVATIVE; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISCRIMINANT ANALYSIS; DRUG UPTAKE; FACTORIAL ANALYSIS; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; KINETICS; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE; VALIDATION STUDY; BRAIN TUMOR; DISEASE FREE SURVIVAL; GLIOMA; MIDDLE AGED; MORTALITY; PROGNOSIS; SCINTISCANNING;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CAMPTOTHECIN; DIDEOXYNUCLEOSIDES; DISCRIMINANT ANALYSIS; DISEASE-FREE SURVIVAL; FEMALE; GLIOMA; HUMANS; MALE; MIDDLE AGED; PROGNOSIS;

EID: 80054103544     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-3290     Document Type: Article

References (35)

1. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 1998;4:1334-6. (Pubitemid 28512118)
2. Bading JR, Shields AF. Imaging of cell proliferation: status and prospects. J Nucl Med 2008;49:64S-80S. (Pubitemid 351948037)
3. Salskov A, Tammisetti VS, Grierson J, Vesselle H. FLT: measuring tumor cell proliferation in vivo with positron emission tomography and 3′-deoxy-3′-[18F]fluorothymidine. Semin Nucl Med 2007;37:429-39. (Pubitemid 47498262)
4. Ullrich R, Backes H, Li H, Kracht L, Miletic H, Kesper K, et al. Glioma proliferation as assessed by 3′-fluoro-3′-deoxy-L-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma. Clin Cancer Res 2008;14:2049-55. (Pubitemid 351551115)
5. 18F]fluorothymidine (FLT) as a marker of proliferation in patients with recurrent gliomas: preliminary efficacy studies. Mol Imaging Biol 2009;11:343-55.
6. 18F-Fluoro- L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors. J Nucl Med 2005;46:1948-58.
7. 18F-Fluorothymidine kinetics of malignant brain tumors. Eur J Nucl Med Mol Imaging 2007;34:1003-11.
8. 18F-FDOPA kinetics in brain tumors. J Nucl Med 2007;48:1651-61.
9. 18F-fluorothymidine in patients with gliomas. J Nucl Med 2006;47:1612-21.
10. 18F-fluorothymidine during treatment monitoring of recurrent high-grade glioma. J Nucl Med 2010;51: 720-7.
11. 18F]fluorothymidine positron emission tomography: a pilot study. J Clin Oncol 2007;25: 4714-21.
12. Galldiks N, Kracht LW, Burghaus L, Thomas A, Jacobs AH, Heiss WD, et al. Use of 11C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas. Eur J Nucl Med Mol Imaging 2006;33:516-24.
13. Chen W. Clinical applications of PET in brain tumors. J Nucl Med 2007;48:1468-81. (Pubitemid 47397397)
14. Wyss M, Hofer S, Bruehlmeier M, Hefti M, Uhlmann C, Bartschi E, et al. Early metabolic responses in temozolomide treated low-grade glioma patients. J Neurooncol 2009;95:87-93.
15. Pope WB, Kim HJ, Huo J, Alger J, Brown MS, Gjertson D, et al. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology 2009;252:182-9.
16. Dhermain FG, Hau P, Lanfermann H, Jacobs AH, van den Bent MJ. Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas. Lancet Neurol 2010;9:906-20.
17. Ballman KV, Buckner JC, Brown PD, Giannini C, Flynn PJ, LaPlant BR, et al. The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro Oncol 2007;9:29-38. (Pubitemid 46543486)
18. Walsh JC, Padgett HC, Ysaguirre T, inventors; Siemens Medical Solutions USA, Inc., assignee. Method for preparing radiolabeled thymidine having low chromophoric byproducts. United States patent US 7419653. 2008 Sept 2.
19. Wu HM, Hoh CK, Choi Y, Schelbert HR, Hawkins RA, Phelps ME, et al. Factor analysis for extraction of blood time-activity curves in dynamic FDG-PET studies. J Nucl Med 1995;36:1714-22.
20. Schiepers C, Hoh CK, DahlbomM,WuHM, Phelps ME. Factor analysis for delineation of organ structures, creation of in- and output functions, and standardization of multicenter kinetic modeling. Proc SPIE 1999;3661:1343-50.
21. Sitek A, Di Bella EV, Gullberg GT. Factor analysis with a priori knowledge-application in dynamic cardiac SPECT. Phys MedBiol 2000;45: 2619-38.
22. Paproski RJ, Ng AM, Yao SY, Graham K, Young JD, Cass CE. The role of human nucleoside transporters in uptake of 3′-deoxy-3′- fluorothymidine. Mol Pharmacol 2008;74:1372-80.
23. Muzi M, Vesselle H, Grierson JR, Mankoff DA, Schmidt RA, Peterson L, et al. Kinetic analysis of 3′-deoxy-3′-fluorothymidine PET studies: validation studies in patients with lung cancer. J Nucl Med 2005; 46:274-82. (Pubitemid 43073435)
24. Muzi M, Mankoff DA, Grierson JR, Wells JM, Vesselle H, Krohn KA. Kinetic modeling of 3′-deoxy-3′-fluorothymidine in somatic tumors: mathematical studies. J Nucl Med 2005;46:371-80. (Pubitemid 43073449)
25. Phelps ME. PET: molecular imaging and its biological applications. New York: Springer; 2004.
26. Afifi AA, Clark V, May S. Computer-aided multivariate analysis. 4th ed. Boca Raton, FL: Chapman & Hall/CRC; 2004.
27. Chan YH. Biostatistics 303. Discriminant analysis. Singapore Med J 2005;46:54-61; quiz 2.
28. Phelps ME. Inaugural article: positron emission tomography provides molecular imaging of biological processes. Proc Natl Acad Sci U S A 2000;97:9226-33. (Pubitemid 30627544)
29. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumours. Nat Rev Neurosci 2007; 8:610-22. (Pubitemid 47093931)
30. Chen YL, Eriksson S, Chang ZF. Regulation and functional contribution of thymidine kinase 1 in repair of DNA damage. J Biol Chem 2010; 285:27327-35.
31. Nimmagadda S, Shields AF. The role of DNA synthesis imaging in cancer in the era of targeted therapeutics. Cancer Metastasis Rev 2008;27:575-87.
32. Goodman LS, Brunton LL, Blumenthal DK, Murri N, Hilal-Dandan R. Goodman & Gilman's the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill Medical; 2011.
33. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006;5:219-34. (Pubitemid 43336035)
34. Loscher W, Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci 2005;6: 591-602. (Pubitemid 41059334)
35. Lamborn KR, Yung WK, Chang SM, Wen PY, Cloughesy TF, DeAngelis LM, et al. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol 2008;10: 162-70.